The cystinosis gene has been reported to reside in a 3.1 cM region of chromosome 17p13 flanked by markers D17S1828 and D17S1798. We created a yeast artificial chromosome (YAC) contig between these markers and report here an integrated genetic and physical map which will aid in the identification of other genes in this area. Using one pertinent YAC clone, 898A10, we identified new polymorphic markers in the cystinosis gene region. One such marker, D17S2167, was localized by radiation hybrid analysis to within 10.2 cR8000 of D17S1828. Haplotype analysis in two separate informative families revealed recombination events which placed the cystinosis gene between markers D17S1828 and D17S2167, an area estimated to be 187-510 kb in size. This dramatic narrowing of the cystinosis gene region permits the creation of a P1 or cosmid contig across the area of interest. The ultimate cloning of the cystinosis gene should eventually reveal how a functional lysosomal transport protein is synthesized, targetted, processed, and integrated into the lysosomal membrane.

Download full-text PDF

Source
http://dx.doi.org/10.1006/bmme.1996.0041DOI Listing

Publication Analysis

Top Keywords

cystinosis gene
24
integrated genetic
8
genetic physical
8
physical map
8
markers d17s1828
8
gene region
8
cystinosis
6
gene
6
fine mapping
4
mapping cystinosis
4

Similar Publications

Background/objectives: Genetic newborn screening (NBS) has already entered the phase of common practice in many countries. In Germany, spinal muscular atrophy (SMA), severe combined immunodeficiency (SCID) and sickle cell disease (SCD) are currently a mandatory part of NBS. Here, we describe the experience of six years of genetic NBS including the prevalence of those three diseases in Germany.

View Article and Find Full Text PDF

Cysteamine, an aminothiol, is the only available treatment for cystinosis, an incurable metabolic recessive disease characterized by detrimental symptoms at the renal, ocular, and muscular levels. Cystinosis is due to mutations in the CTNS gene encoding for the lysosomal symporter cystinosine. Cysteamine treatment only delays the symptoms, presents undesirable side effects and the patients depend on it for life.

View Article and Find Full Text PDF
Article Synopsis
  • Imerslund-Gräsbeck syndrome (IGS) is a rare genetic condition that leads to anemia and the body not absorbing vitamin B12 properly.
  • A 23-month-old baby in Italy was diagnosed with IGS after showing serious health issues, but vitamin B12 treatment helped improve the situation.
  • Genetic tests revealed two unusual changes in a specific gene, which are linked to the condition, and it's important to diagnose IGS early to avoid serious problems.
View Article and Find Full Text PDF

Leptin signalling altered in infantile nephropathic cystinosis-related bone disorder.

J Cachexia Sarcopenia Muscle

December 2024

Division of Pediatric Nephrology, Rady Children's Hospital, University of California, San Diego, La Jolla, CA, USA.

Background: The CTNS gene mutation causes infantile nephropathic cystinosis (INC). Patients with INC develop Fanconi syndrome and chronic kidney disease (CKD) with significant bone deformations. C57BL/6 Ctns mice are an animal model for studying INC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!